
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
over 18 years ago
Newcomer (Am J Manag Care. 2007;13[suppl 7]:S170-S177)over 18 years ago
Cost-effectiveness of Telephonic Disease Management in Heart Failureover 18 years ago
Practice Systems Are Associated With High-quality Care for Diabetes




